Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MCL1 | Q07820 | 6/20 | 0.46 |
| ▸ | RORC | P51449 | 5/20 | 0.45 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.37 |
| ▸ | NR1H2 | P55055 | 4/20 | 0.37 |
| ▸ | MMP2 | P08253 | 1/20 | 0.37 |
| ▸ | MMP9 | P14780 | 1/20 | 0.37 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.36 |
| ▸ | TP53 | P04637 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | BCL2L1 | Q07817 | 1/20 | 0.36 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15772054 | 0.78 | MCL1 (0.66) | MCL1RORCTSHRMAPK1KMT2A | |
| SCHEMBL15772696 | 0.75 | RORC (0.58) | RORC | |
| SCHEMBL15780656 | 0.75 | ALDH1A1 (0.56) | MCL1RORCTSHRMAPK1KMT2A | |
| SCHEMBL17276835 | 0.75 | RORC (0.78) | RORC | |
| SCHEMBL28129570 | 0.74 | MCL1 (0.62) | MCL1RORCTSHRMAPK1KMT2A | |
| SCHEMBL15806720 | 0.71 | RORC (0.45) | MCL1RORC | |
| SCHEMBL17843295 | 0.71 | MCL1 (0.58) | MCL1RORCTSHRMAPK1KMT2A | |
| SCHEMBL15772527 | 0.69 | MCL1 (0.75) | MCL1RORCTSHRMAPK1KMT2A | |
| SCHEMBL18392319 | 0.69 | MCL1 (0.75) | MCL1RORCTSHRMAPK1KMT2A | |
| SCHEMBL17852218 | 0.68 | S1PR1 (0.50) | MCL1RORCTSHRMAPK1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9382222-B2 | Benzyl sulfonamide derivatives as RORc modulators | GENENTECH, INC. (US) | 2016-07-05 | — | — | US | disclosed |
| US-9382222-B2 | Benzyl sulfonamide derivatives as RORc modulators | GENENTECH, INC. (US) | 2016-07-05 | — | — | US | disclosed |
| US-9302985-B2 | Benzyl sulfonamide derivatives as RORc modulators | GENENTECH, INC. (US) | 2016-04-05 | — | — | US | disclosed |
| US-9302985-B2 | Benzyl sulfonamide derivatives as RORc modulators | GENENTECH, INC. (US) | 2016-04-05 | — | — | US | disclosed |
| WO-2015177325-A1 | BENZENE SULFONAMIDE DERIVATIVES AND THEIR USE AS RORC MODULATORS | F. HOFFMANN-LA ROCHE AG (CH) | 2015-11-26 | — | — | WO | disclosed |
| WO-2014090710-A1 | BENZYL SULFONAMIDE DERIVATIVES AS RORc MODULATORS | F. HOFFMANN-LA ROCHE AG (CH) | 2014-06-19 | — | — | WO | disclosed |
| US-20140163110-A1 | BENZYL SULFONAMIDE DERIVATIVES AS RORc MODULATORS | GENENTECH, INC. (US) | 2014-06-12 | — | — | US | disclosed |
| US-20140163024-A1 | BENZYL SULFONAMIDE DERIVATIVES AS RORc MODULATORS | GENENTECH, INC. (US) | 2014-06-12 | — | — | US | disclosed |
| US-20140163110-A1 | BENZYL SULFONAMIDE DERIVATIVES AS RORc MODULATORS | GENENTECH, INC. (US) | 2014-06-12 | — | — | US | disclosed |
| US-20140163024-A1 | BENZYL SULFONAMIDE DERIVATIVES AS RORc MODULATORS | GENENTECH, INC. (US) | 2014-06-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140163110-A1 | BENZYL SULFONAMIDE DERIVATIVES AS RORc MODULATORS | RORC, RORA, RORB | MCL1 1532/4885RORC 1/4885TSHR 159/4885 |
| US-20140163024-A1 | BENZYL SULFONAMIDE DERIVATIVES AS RORc MODULATORS | RORC, RORA, RORB | MCL1 1899/4885RORC 1/4885TSHR 285/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.